Tecentriq (Atezolizumab) is a fully humanized, engineered monoclonal antibody of IgG1isotype against the protein programmed cell death-ligand 1 (PD-L1).
TECENTRIQ (ATEZOLIZUMAB) INDICATION AND USAGE:
In May 2016 FDA approved Tecentriq (Atezolizumab) for locally advanced or metastatic urothelial carcinoma treatment after failure of cisplatin-based chemotherapy.
In October 2016, FDA approved Tecentriq (Atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy
DOSAGE FORM & STRENGTH:
Tecentriq (Atezolizumab) 1200mg/20ml Wholesaler
Rasso Swiss Pharma is a wholesaler, distributor, supplier for Tecentriq (Atezolizumab).